The pharmaceutical company Sobi announces that CEO Guido Oelkers is leaving the company. In a press release, it says that Oelkers has decided to leave for another assignment.
"Guido Oelkers will remain in his role as CEO until the end of January 2027 at the latest. The board will immediately initiate a process to ensure a structured leadership transition and appoint a new CEO," the company writes in the press release.
The biopharmaceutical company Sobi has surged on the Stockholm Stock Exchange this year, and the share is up 40 percent since the turn of the year.
